<!DOCTYPE HTML>
<!--
	Massively by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>Publications</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
		<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Header -->
					<header id="header">
						<a href="index.html" class="logo">Projects</a>
					</header>

				<!-- Nav -->
					<nav id="nav">
						<ul class="links">
							<li><a href="index.html">Projects</a></li>
							<li class="active"><a href="generic.html">Research Publications</a></li>
							<li><a href="elements.html">Other</a></li>
						</ul>
						<ul class="icons">
							<li><a href="https://www.linkedin.com/in/sarah-warda/" class="icon brands alt fa-linkedin"><span class="label">Linkedin</span></a></li>
							<li><a href="https://github.com/sarwarda" class="icon brands alt fa-github"><span class="label">GitHub</span></a></li>
						</ul>
					</nav>

				<!-- Main -->
					<div id="main">

						<!-- Post -->
							<section class="post">
								<header class="major">
									<h2>Research Publications<br />
									</h2>
									</header>
									<a href="#" class="image fit"><img src="images/pic06.jpg" alt="" /></a>
								<dl>
								<dt>[1] <b>PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry</b>
								</dt>
									<dd>
										<p> Patel, Amish J., <b>Warda, Sarah,</b> Maag, Jesper L. V., Misra, Rohan, Miranda-Román, Miguel A., Pachai, Mohini 
										R., Lee, Cindy J., Li, Dan, Wang, Naitao, Bayshtok, Gabriella, Fishinevich, Eve, Meng, Yinuo, Wong, Elissa W. P., 
										Yan, Juan, Giff, Emily, Pappalardi, Melissa B., McCabe, Michael T., Fletcher, Jonathan A., Rudin, Charles M., … Chi, Ping. 
										(2022). PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. 
										In Cancer Discovery (Vol. 12, Issue 9, pp. 2120–2139). American Association for Cancer Research (AACR).
									 	<a href="https://doi.org/10.1158/2159-8290.CD-21-1671"> https://doi.org/10.1158/2159-8290.CD-21-1671</a></p>
									 
									 		<blockquote> Polycomb Repressive Complex 2 (PRC2) has oncogenic and tumor suppressor roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2 inactivating mutations are a hallmark feature of high-grade malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma with poor prognosis and no effective targeted therapy. Through RNAi screening in MPNST, we found that PRC2-inactivation increases sensitivity to genetic or small molecule inhibition of DNA methyltransferase 1 (DNMT1), which results in enhanced cytotoxicity and antitumor response. Mechanistically, PRC2 inactivation amplifies DNMT inhibitor (DNMTi) mediated expression of retrotransposons, subsequent viral mimicry response, and robust cell death in part through PKR-dependent double stranded-RNA (dsRNA) sensor. Collectively, our observations posit DNA methylation as a safeguard against anti-tumorigenic cell fate decisions in PRC2-loss cancer to promote cancer pathogenesis, which can be therapeutically exploited by DNMT1 targeted therapy. </blockquote>
									</dd>
								<hr>
								<dt> [2] <b>Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by 
										immunogenic viruses</b>
								</dt>
									<dd>
										<p> Yan, Juan, Chen, Yuedan, Patel, Amish J., <b>Warda, Sarah,</b> Lee, Cindy J., Nixon, Briana G., Wong, Elissa W. P., 
										Miranda-Román, Miguel A., Yang, Ning, Wang, Yi, Pachai, Mohini R., Sher, Jessica, Giff, Emily, Tang, Fanying, 
										Khurana, Ekta, Singer, Sam, Liu, Yang, Galbo, Phillip M., Jr., Maag, Jesper L. V., … Chi, Ping. (2022). 
										Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by 
										immunogenic viruses. In Journal of Clinical Investigation (Vol. 132, Issue 17). American Society for Clinical Investigation. 
										<a href="https://doi.org/10.1172/JCI153437"> https://doi.org/10.1172/JCI153437</a> </p>
											
											<blockquote> Immune checkpoint blockade (ICB) has demonstrated clinical success in “inflamed” tumors with substantial T-cell infiltrates, but tumors with an immune-desert tumor microenvironment (TME) fail to benefit. The tumor cell-intrinsic molecular mechanisms of the immune-desert phenotype remain poorly understood. Here, we demonstrated that inactivation of the Polycomb-repressive complex 2 (PRC2) core components, EED or SUZ12, a prevalent genetic event in malignant peripheral nerve sheath tumor (MPNST) and sporadically in other cancers, drove a context-dependent immune-desert TME. PRC2 inactivation reprogramed the chromatin landscape that led to a cell-autonomous shift from primed baseline signaling-dependent cellular responses (e.g., interferon γ) to PRC2-regulated development and cellular differentiation transcriptional programs. Further, PRC2 inactivation led to diminished tumor immune infiltrates through reduced chemokine production and impaired antigen presentation and T-cell priming, resulting in primary resistance to ICB. Intratumoral delivery of inactivated modified vaccinia virus Ankara (MVA) enhanced tumor immune infiltrates and sensitized PRC2-loss tumors to ICB. Our results provide molecular mechanisms of PRC2-inactivation-mediated context-dependent epigenetic reprogramming that underline the immune-desert phenotype in cancer. Our studies also point to intratumoral delivery of immunogenic viruses as an initial therapeutic strategy to modulate the immune-desert TME and capitalize on the clinical benefit of ICB.</blockquote>
									</dd>
									<hr>
								<dt> [3] <b>Phase II Trial of Imatinib Plus Binimetinib in Patients With 
									Treatment-Naive Advanced Gastrointestinal Stromal Tumor</b>

								</dt>
									<dd>
										<p>Chi, P., Qin, L. X., Nguyen, B., Kelly, C. M., D'Angelo, S. P., Dickson, M. A., Gounder, M. M., Keohan, M. L., Movva, S., 
											Nacev, B. A., Rosenbaum, E., Thornton, K. A., Crago, A. M., Yoon, S., Ulaner, G., Yeh, R., Martindale, M., Phelan, H. T., 
											Biniakewitz, M. D., <b>Warda, S.</b>, … Tap, W. D. (2022). Phase II Trial of Imatinib Plus Binimetinib in Patients With 
											Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of clinical oncology : official journal of the American 
											Society of Clinical Oncology, 40(9), 997–1008. 
											<a href="https://doi.org/10.1200/JCO.21.02029"> https://doi.org/10.1200/JCO.21.02029</a></p>
											
											<blockquote> Dual targeting of the gastrointestinal stromal tumor (GIST) lineage-specific master regulators, ETV1 and KIT, by MEK and KIT inhibitors were synergistic preclinically and may enhance clinical efficacy. This trial was designed to test the efficacy and safety of imatinib plus binimetinib in first-line treatment of GIST.</blockquote>
									</dd>		
									<hr>					
								</dl>
							
							</section>

					</div>

				<!-- Footer -->
					<footer id="footer">
						<section class="split contact">
							<section>
								<h3>Email</h3>
								<p><a href="#">sarah.warda96@gmail.com </a></p>
							</section>
							<section>
								<h3>Social</h3>
								<ul class="icons alt">
									<li><a href="https://www.linkedin.com/in/sarah-warda/" class="icon brands alt fa-linkedin"><span class="label">Linkedin</span></a></li>
									<li><a href="https://github.com/sarwarda" class="icon brands alt fa-github"><span class="label">GitHub</span></a></li>
								</ul>
							</section>
						</section>
					</footer>

				<!-- Copyright -->
					<div id="copyright">
						<ul><li>&copy; Sarah Warda</li></ul>
					</div>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/jquery.scrollex.min.js"></script>
			<script src="assets/js/jquery.scrolly.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

	</body>
</html>